Tüdőrák: vizsgálatok itt: Thaiföld

32 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

• 4. fázisTaking people
  Dabrafenib and/or Trametinib Rollover Study

  Where

  Songkhla

  Életkor

  18 év to 100 év

  People

  100 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT03340506 · EU 2023-509318-13-00
• 2. fázisTaking people
  KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  Where

  Bangkok

  Életkor

  18 év and over

  People

  140 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07252739 · EU 2025-521939-36-00
• 3. fázisTaking people
  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  Where

  Bangkok, Hat Yai, Muang

  Életkor

  18 év and over

  People

  400 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07291037 · EU 2024-520101-39-00
• 3. fázisTaking people
  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  Where

  Bangkok, Chiang Mai, Hat Yai

  Életkor

  18 év and over

  People

  670 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07472517 · EU 2025-520565-51-00
• 3. fázisTaking people
  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  Where

  Bangkok, Din Daeng

  Életkor

  18 év and over

  People

  850 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07680790 · EU 2026-526486-21-00
• 3. fázisTaking people
  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  Where

  Bangkoknoi, Hat Yai, Muang, Ratchathewi

  Életkor

  18 év and over

  People

  680 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06623422 · EU 2023-506327-29-00
• 1/2. fázisTaking people
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

  Where

  Bangkok, Bangkoknoi, Hat Yai

  Életkor

  18 év to 64 év

  People

  170 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07227597 · EU 2025-521032-11-00
• 3. fázisTaking people
  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  Where

  Bangkok, Chiang Mai, Khon Kaen, Samut Sakhon, Songkhla

  Életkor

  18 év to 100 év

  People

  750 worldwide

  Run by

  Amgen

  See details and how to joinNCT05920356 · EU 2022-501863-41-00
• 1/2. fázisTaking people
  A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

  Where

  Hat Yai, Thung Phaya Thai

  Életkor

  18 év and over

  People

  315 worldwide

  Run by

  Voronoi, Inc

  See details and how to joinNCT07699328 · EU 2025-523122-40-00
• 3. fázisTaking people
  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  Where

  Bangkok, Chiang Mai, Khon Kaen, Songkhla

  Életkor

  18 év and over

  People

  850 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07361497 · EU 2025-523576-23-00
• 3. fázisTaking people
  Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  Where

  Bangkok, Muang, Pathumwan

  Életkor

  18 év and over

  People

  614 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06170788 · EU 2023-503376-24-00
• 2/3. fázisTaking people
  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  Where

  Bangkok, Chiang Rai, Lampang, Nakhon Nayok, Ratchathewi

  Életkor

  18 év and over

  People

  1580 worldwide

  Run by

  BioNTech SE

  See details and how to joinNCT06712316 · EU 2024-515764-31-00
• 3. fázisTaking people
  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  Where

  Bangkok, Bangkoknoi, Hat Yai, Lak Si

  Életkor

  18 év and over

  People

  480 worldwide

  Run by

  ArriVent BioPharma, Inc.

  See details and how to joinNCT07185997
• 2/3. fázisTaking people
  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  Where

  Bangkok

  Életkor

  18 év and over

  People

  626 worldwide

  Run by

  Mirati Therapeutics Inc.

  See details and how to joinNCT04613596 · EU 2023-508922-83-00
• 3. fázisTaking people
  Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  Where

  Bangkok, Bangkoknoi, Hat Yai, Lampang, Muang, Mueang

  Életkor

  18 év and over

  People

  851 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06422143 · EU 2023-510128-66-00
• 3. fázisTaking people
  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  Where

  Bangkok, Chiang Mai, Dusit, Nakhon Ratchasima, Songkhla

  Életkor

  18 év and over

  People

  1160 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06692738 · EU 2024-514281-39-00
• 3. fázisTaking people
  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  Where

  Bangkok, Hat Yai, Muang, Mueang

  Életkor

  18 év and over

  People

  675 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06357533 · EU 2023-505077-32-00
• 3. fázisTaking people
  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  Where

  Bangkok, Chiang Mai, Dusit, Nakhon Ratchasima, Songkhla

  Életkor

  18 év and over

  People

  1160 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06627647 · EU 2024-515008-38-00
• 1/2. fázisTaking people
  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  Where

  Bangkok, Chanthaburi, Hat Yai, Khon Kaen, Rachathewi

  Életkor

  18 év and over

  People

  152 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06996782 · EU 2024-519786-22-01
• 3. fázisTaking people
  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  Where

  Bangkok, Hat Yai, Muang

  Életkor

  18 év and over

  People

  630 worldwide

  Run by

  Mirati Therapeutics Inc.

  See details and how to joinNCT06875310 · EU 2024-515698-85-00
• 3. fázisTaking people
  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  Where

  Bangkok, Dusit, Hat Yai, Laksi, Rajathevee

  Életkor

  18 év and over

  People

  686 worldwide

  Run by

  Daiichi Sankyo

  See details and how to joinNCT06899126 · EU 2024-515658-26-00
• 2/3. fázisTaking people
  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  Where

  Bangkok

  Életkor

  18 év and over

  People

  590 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07063745 · EU 2025-521511-40-00
• 3. fázisTaking people
  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  Where

  Bangkok, Chiang Mai, Khon Kaen, Songkhla

  Életkor

  18 év and over

  People

  750 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07361510 · EU 2025-523586-18-00
• 2. fázisTaking people
  A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

  Where

  Bangkok, Banphaeo

  Életkor

  18 év and over

  People

  278 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07098338 · EU 2025-524843-11-00
• 1/2. fázisTaking people
  A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  Where

  Bangkok, Chiang Mai

  Életkor

  18 év and over

  People

  460 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT05123482 · EU 2022-502759-70-01